Revenue segments as reported by the company.

Life Sciences and Applied Markets Group

Diagnostics and Genomics Group

Agilent CrossLab Group

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Agilent Technologies

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Agilent Technologies posts strong Q1 earnings, eyes PFAS testing and CRISPR expansion

Agilent Technologies delivered robust Q1 results, raised full-year guidance, and remains confident in its growth drivers. Despite challenges in the genomics market and uncertainties ahead, the company is strategically positioned to capitalize on opportunities and drive continued success.

Agilent reports strong Q2 earnings but revises down second-half forecast

Agilent Technologies delivered strong Q2 results but revised down second-half forecasts due to economic uncertainties. The company remains focused on driving margin expansion, cost efficiencies, and customer service excellence. Challenges from macroeconomic factors and market dynamics are being addressed with a strategic outlook for long-term growth.

Agilent Technologies faces China revenue challenges but eyes growth opportunities

Agilent Technologies faces revenue challenges in China but sees growth opportunities in companion diagnostics and liquid biopsy markets. The company remains confident in its ability to drive earnings growth despite recent setbacks.

Agilent reports mixed Q4 results, eyes steady recovery in 2024

Agilent Technologies reported mixed Q4 results with revenue decline but exceeded EPS guidance. While facing challenges in China and certain segments, the company anticipates slow but steady recovery for FY 2024. Agilent is focusing on cost-saving measures, pricing trends, and investments in growth areas like genomics and environmental solutions.

Agilent reports Q1 revenue decline, eyes global growth opportunities

Agilent Technologies' Q1 performance showed revenue decline but with strengths in certain segments like ACG and consumables. Challenges include revenue declines in DGG and LSAG impacting margins. Opportunities lie in global growth prospects and potential market surprises.

Agilent Technologies faces revenue decline but eyes growth opportunities ahead

Agilent Technologies navigated a challenging market in Q2 2024 with revenue declines across all end markets. The company remains focused on customer-centric strategies, cost optimization, and growth investments while addressing visibility challenges and exploring opportunities in high-growth segments.

Agilent reports Q3 earnings beat, eyes growth through acquisitions

Agilent Technologies delivered a solid performance in Q3 2024, exceeding earnings per share guidance and raising revenue and EPS midpoint guidance.
While facing revenue decline, the company's strategic investments and acquisitions signal a focus on growth and innovation.
Challenges include market dynamics and integration risks, but opportunities exist in leveraging digital initiatives and financial strength for future growth.

Agilent Technologies reports robust Q4 performance and outlines growth strategies

Agilent Technologies' Q4 2024 earnings call highlighted strong financial performance, strategic acquisitions, and a focus on margin expansion for sustainable growth.
Despite regional challenges and market uncertainties, the company remains optimistic about future prospects and is committed to driving EPS growth.
With a new market-focused approach and ongoing transformation initiatives, Agilent is well-positioned to capitalize on opportunities and navigate potential challenges in FY 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent to announce fiscal second quarter financial results on May 25.

Agilent to Webcast Second-Quarter Fiscal Year 2021 Financial Results Presentation

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today that both the InfinityLab LC/MSD iQ and the Ultivo Triple Quadrupole LC/MS systems have earned the highly-respected Accountability, Consistency and Transparency (ACT) Label from My Green Lab, a nonprofit organization dedicated to improving the sustainability of scientific research. “Agilent's mission is to provide trusted answers and insights that advance the quality of life, and sustainability is an impor

Agilent LC/MS Instruments Receive ACT Labels from My Green Lab

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies (NYSE: A) today was named one of the top U.S. companies for diversity, marking the third straight year it has been recognized for its commitment to fostering a diverse and inclusive workplace. Specifically, Agilent ranked No. 83 out of 500 companies on Forbes's 2021 list of America's Best Employers for Diversity. The rating was based on dimensions of diversity including gender, ethnicity, LGBTQ+, age, and the differently abled. Agilent

Agilent Named One of the Best U.S. Companies for Diversity for Third Straight Year

PHILADELPHIA--(BUSINESS WIRE)--Macquarie Asset Management (“MAM”) today announced the launch of The Sharpe Advisor, a specialized digital resource for financial advisors that provides comprehensive educational content on private markets. With education as a key driver of success in bringing alternative investment solutions to financial advisors and their clients, Macquarie Asset Management aims to serve advisors with a practical guide to private markets investing with specialized content from i

Macquarie Asset Management Launches “The Sharpe Advisor” Digital Educational Platform for Advisors Centered Around Private Markets

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent completes acquisition of Resolution Bioscience.

Agilent Completes Acquisition of Resolution Bioscience, Expands Role in Fast-growing NGS Market for Precision Oncology

SINGAPORE--(BUSINESS WIRE)--Agilent Technologies announced that Agilent Singapore has been recognized as one of Singapore's Best Employers in 2021 for the second year-in-a-row.

Agilent Named One of Singapore's Best Employers

Agilent (A) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Agilent (A) Moves to Strong Buy: Rationale Behind the Upgrade

Agilent isn't a conventionally cheap stock, but should offer above-average revenue growth and margin expansion over the next five to 10 years, with leverage to several growth segments with biopharma. Agilent has been gaining share in instruments and demand should improve as lab activities and budgets normalize after the pandemic, with automation a longer-term growth driver.

Agilent Leveraged To Post-Pandemic Recovery And Advanced Drug Discovery And Production

OXFORD, England--(BUSINESS WIRE)--Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for personalized healthcare based on the EpiSwitch® 3D genomics platform, and Agilent Technologies (NYSE: A), a global leader in the life sciences, diagnostics, and applied chemical markets, have signed a supply and resale agreement for the manufacture and sale of the new EpiSwitch® Explorer Array Kit (“Kit”). Under the terms of the agreement, Agilent wil

Oxford BioDynamics signs supply and resale agreement with Agilent Technologies, and launches EpiSwitch® Explorer Array Kit for R&D use

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announces that Octagon Therapeutics has been awarded an Agilent Golden Ticket at LabCentral. The Golden Ticket was presented to Octagon during a virtual online event on March 24 and provides funding for one scientist's lab bench space for a year, including the benefit of LabCentral's shared infrastructure and services. The three semi-finalists, Octagon Therapeutics, Rizana Therapeutics, and Nuakea Therapeutics presented c

Agilent Awards Octagon Therapeutics with a Golden Ticket at LabCentral

Agilent (A) reported earnings 30 days ago. What's next for the stock?

Why Is Agilent (A) Down 5.8% Since Last Earnings Report?

Agilent (A) unveils 8697 Headspace Sampler which unprecedented precision and strong connections.

Agilent (A) Boosts Intelligence Capability With a New Launch

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today introduced the Agilent 8697 Headspace Sampler, the first headspace sampler with integrated gas chromatography communication. It marks the expansion of intelligence capability that was first launched with the Agilent Intuvo 9000 GC System in 2016 and later in 2019 with the Agilent 8890 and 8860 GC Systems. “We recognized the increasing needs of our customers, especially in the pharma space, to have greater remote acc

Agilent Announces the 8697 Headspace Sampler with Integrated Intelligence

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent names Dr. Kate Knobil as the company's first chief medical officer.

Dr. Katharine Knobil Named Agilent's First Chief Medical Officer

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of a real-time reverse transcription (qRT) PCR-based diagnostic kit for the detection of SARS-CoV-2 RNA. The CE-IVD mark is in accordance with the European Union In Vitro Diagnostic Directive 98/79/EC and is available for immediate distribution. The Agilent SARS-CoV-2 qRT-PCR Dx kit is a real-time reverse transcriptase PCR (qRT-PCR) IVD reagent kit for the detection of SARS-CoV-2 RNA. Agilent's

Agilent Completes CE-IVD Registration of qRT-PCR In Vitro Diagnostic Kit for SARS-CoV-2 RNA Detection

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies announces pricing of $850 million of senior notes.

Agilent Technologies Announces Pricing of $850 Million of Senior Notes

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies announces proposed offering of senior notes.

Agilent Technologies Announces Proposed Offering of Senior Notes

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Growth--Agilent to acquire Resolution Bioscience, strengthening leadership position in cancer diagnostics.

Agilent to Acquire Resolution Bioscience, Strengthening Leadership Position in Cancer Diagnostics

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the recipient of the 2021 Darlene Solomon Award is Noemi Jiménez-Rojo, a postdoctoral fellow studying membrane biology, lipid diversity, and function at the University of Geneva. The award was presented at a virtual ceremony during the International Singapore Lipid Symposium (iSLS) being held March 1-5 in Singapore. “Multidisciplinary approaches that include mass spectrometry will be crucial in the fo

Agilent Announces Darlene Solomon Award Presented to University of Geneva Scientist Noemi Jiménez-Rojo

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's PD-L1 IHC 22C3 pharmDx assay for expanded use in patients with non-small cell lung cancer (NSCLC). PD-L1 IHC 22C3 pharmDx can now be used as an aid in identifying NSCLC patients with tumor PD-L1 expression of Tumor Proportion Score (TPS) ≥ 50% for treatment with Libtayo® (cemiplimab-rwlc). This announcement underscores Agilent's co

Agilent PD-L1 IHC 22C3 pharmDx Receives Expanded FDA Approval in Non-small Cell Lung Cancer (NSCLC)

Hilton Worldwide Holdings

Lowe's

Restaurant Brands

Starbucks

Bill Ackman ( Trades , Portfolio ), leader of Pershing Square Capital, has revealed his portfolio for the fourth quarter of 2020. The top five trades of the quarter were reductions made in Starbucks Corp. (NASDAQ:SBUX), Restaurant Brands International Inc. (NYSE:QSR), Lowe's Companies Inc. (NYSE:LOW), Agilent Technologies Inc. (NYSE:A) and Hilton Worldwide Holdings Inc. (NYSE:HLT).

Bill Ackman Slims Down Top Holdings in 4th Quarter

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) has earned the number two position on Barron's annual list of America's Most Sustainable Companies. The ranking marks the third straight year Agilent has been included among the top three Most Sustainable Companies. Agilent has also received the number one ranking in the life sciences industry for each of the four years the Barron's ranking has been compiled. “We're very pleased to again be named one of America's Most Sus

Agilent Ranks No. 2 on Barron's List of America's Most Sustainable Companies

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of the Agilent Dako SARS-CoV-2 IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit intended for the qualitative detection of immunoglobulin G (IgG) antibodies to SARS-CoV-2 in human serum or plasma. The kit, which marks Agilent's entrance into SARS-CoV-2 testing in the US, has completed the notification process to FDA in accordance with Section IV.D of FDA's “Policy for Coronavirus Disease-2019 Te

Agilent Announces Immunoassay Kit to Detect SARS-CoV-2 Antibodies

Agilent Technologies' (A) fiscal first-quarter results reflect growth in all segments and regions served.

Agilent's (A) Q1 Earnings Beat Estimates, Revenues Up Y/Y

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today introduced the Agilent Seahorse XF HS Miniplate designed specifically for the Agilent Seahorse XF HS Mini Analyzer for improved immune cell metabolic analysis. Immunology and disease researchers are increasingly using rare, ex vivo, and genetically engineered cells to build better disease models. Limitations in the quantities of these cells that they can produce, however, restrict these researchers in the types of c

News for Agilent Technologies Stock (A)